Skip navigation

Should women use sildenafil to reduce their risk of Alzheimer’s disease? Elizabeth Tracey reports

Sildenafil > women sildenafil


Participants applied the investigational product about 10–20 minutes before the sexual event. One gram was applied externally to the anterior labial commissure, prepuce of the clitoris, glans, frenulum, vestibule, and labia minora.

Risk Details Precaution
Cardiovascular complications Increased blood pressure, arrhythmias Screen for cardiovascular disease before use
Drug interactions Severe hypotension, adverse effects from combinations Complete medication history before prescribing
Allergic reactions Rashes, swelling, difficulty breathing Discontinue and seek medical attention if occurs
Psychological dependency Over-reliance on medication for arousal Counseling for emotional health
Misuse and overdose Increased adverse effects Strict adherence to prescribed dose

The other gram was applied to the anterior distal vagina to an approximate depth of 0–3 cm or about halfway between the distal and proximal interphalangeal joints, targeting the distal, lower one-third of the vagina. Participants were instructed to wash off the cream and have their partner wash off the cream, if relevant, after the sexual experience. The Arousal Sensation domain of the SFQ28 questionnaire is made up of questions 6 through 9 (Appendix 2, available online at These four questions were answered using a Likert scale ranging from 1–5, with 1 being no sensation and 5 being a very strong sensation.

What special precautions should I follow?

The range of scores for the Arousal Sensation domain is 4–20, with higher scores indicating higher sexual function.

Product Dosage Quantity + Bonus Price
Kamagra Polo100mg272 + 12 Pills622.94€ 593.28€
Viagra Generic50mg120 + 6 Pills129.64€ 123.47€
Kamagra Polo100mg12 Pills60.21€ 57.34€
Viagra Generic50mg270 + 8 Pills198.48€ 189.03€
Viagra Generic150mg60 + 4 Pills111.25€ 105.95€
Viagra Generic50mg10 Pills26.87€ 25.59€
Viagra Generic25mg360 + 10 Pills213.68€ 203.50€
Viagra Generic50mg360 + 10 Pills225.33€ 214.60€
Kamagra Soft Tabs100mg272 + 12 Pills593.42€ 565.16€
Viagra Generic200mg270 + 10 Pills379.76€ 361.68€

The FSDS-DAO survey includes 15 questions, each of which began with the phrase, “How often in the past 30 days did you feel,” with responses of 0–4, with 0 indicating never feeling this way and 4 indicating always feeling this way (Appendix 2, Question 14 asks, “How often in the past 30 days did you feel concerned by difficulties with sexual arousal?” The range of scores for question 14 of the FSDS-DAO is 0–4, with lower scores indicating decreased levels of sexual distress. For the secondary efficacy endpoint, the electronic diary prompted women every 24 hours to report whether there had been a sexual event. If there was a sexual event, the electronic diary prompted the participant to answer several questions, including, “Did you consider sexual activity satisfactory for you?” The secondary endpoint was the change from baseline at week 12 in the average number and proportion of satisfactory sexual events per product cohort. Prespecified exploratory endpoints are detailed in Appendix 2, This study was designed as an exploratory, preliminary efficacy study.

Medical uses

The mean proportion of satisfactory sexual events was also similar between the two dosing cohorts (all P>.15). The only statistically significant change noted for the ITT population was a statistically significant increase in the SFQ28 Desire domain score at week 8 for sildenafil cream users (P=.04, Table 2), which was a predefined exploratory endpoint. Efficacy Endpoints for the Intention-to-Treat Population* When the efficacy endpoints were compared in an exploratory post hoc analysis based on enrollment sexual dysfunction diagnoses, women with female sexual arousal disorder with concomitant orgasmic dysfunction did not experience as large a treatment benefit at week 12 from sildenafil cream use (data not shown, all P>.22) as those with other sexual dysfunction diagnoses. Specifically, women with female sexual arousal disorder as their only sexual dysfunction, although uncommon, experienced the largest improvements in sexual function at week 12 with sildenafil cream (Table 3), which were not statistically significant, likely because of the small sample size. When participants with female sexual arousal disorder with concomitant orgasmic dysfunction and female sexual arousal disorder with concomitant genital pain were removed from the analysis, a subset of participants (sildenafil 33 and placebo 32) remained.

How it Helps You Do It

This subset of participants, who had female sexual arousal disorder only or female sexual arousal disorder with concomitant decreased desire, experienced significant improvements with sildenafil cream use at week 12 in the coprimary endpoint of SFQ28 Arousal Sensation domain (P=.04, Table 3) and had large improvements in the SFQ28 Desire domain (P=.06, Table 3) and the SFQ28 Orgasm domain (P=.19, Table 3) at week 12 compared with placebo cream users. Efficacy Endpoints for Enrollment Female Sexual Dysfunction Diagnoses Subset Population* Although the subset population of women randomized to sildenafil cream with either female sexual arousal disorder only or female sexual arousal disorder with concomitant decreased desire did not demonstrate statistically significant decreased sexual distress as measured by the coprimary endpoint of FSDS-DAO question 14 (P=.95, Table 3), which assesses concern about difficulties with sexual arousal, we found that several other FSDS-DAO questions, which asked about generalized feelings related to sexual distress and interpersonal difficulties, showed significant improvement with sildenafil cream compared with placebo cream (questions 3, 5 and 10, all P≤.04, Table 3) in this exploratory subset. The total FSDS-DAO score decreased by about 7 points for sildenafil cream users in the subset population (a clinically meaningful decrease in sexual distress11) compared with a 2-point decrease for placebo cream users (P=.10). Topical sildenafil cream used over 12 weeks among healthy premenopausal women with female sexual arousal disorder did not show statistically significant improvement over placebo in the coprimary (SFQ28 Arousal Sensation domain, FSDS-DAO question 14) or secondary (mean number and mean proportion of satisfactory sexual events) endpoints among the ITT population, all of whom had female sexual arousal disorder but had a wide variety of concomitant sexual dysfunction diagnoses or symptoms, during this exploratory phase 2b study. This study required the participants' main sexual dysfunction to be related to arousal because the mechanism of action of topical sildenafil citrate is to augment genital tissue blood flow to treat female sexual arousal disorder.18–28 Not surprisingly, we saw that female sexual arousal disorder was often accompanied by concomitant sexual dysfunction diagnoses or symptoms.29,30 When the efficacy endpoints were compared in an exploratory post hoc analysis among a subset of women with female sexual arousal disorder only or female sexual arousal disorder with concomitant decreased desire, we found either trends or significant improvements in sexual functioning with sildenafil cream compared with placebo cream across multiple aspects of sexual function. Assuming an estimated dropout rate of 25%, about 400–590 patients were planned to be randomized to the double-blind dosing period to ensure that a total of 300–440 patients successfully completed the double-blind dosing period (150–220 patients for each arm). Under the assumption of an SD of 4.7 for change from baseline to end of study in the SFQ28 Arousal Sensation domain and based on a previous study of oral sildenafil use in women with female sexual arousal disorder12 and a SD of 1.2 for change from baseline to end of study in question 14 of the FSDS-DAO, 300 patients would have provided more than 90% marginal power for the primary objective tests on the coprimary endpoints, with a target difference of +2 points in the change from baseline at week 12 in the SFQ28 Arousal Sensation domain and −0.5 in the change from baseline at week 12 in question 14 of the FSDS-DAO. Several studies further support the initial sample size calculations include.13–17 However, as a result of slower-than-anticipated enrollment (because of the requirement to obtain consent from and to enroll the patient's sexual partner and the effect of the coronavirus disease 2019 [COVID-19] pandemic) and considering the exploratory nature of the study, the sponsor decided that a smaller sample size, although resulting in underpowering, was acceptable and halted recruitment in August 2022. The protocol was revised to randomize 169–175 patients to ensure that a minimum of 150 patients completed the study, even though that sample size would not be sufficient to achieve the 300 patients estimated to provide more than 90% marginal power for the primary objective tests on the coprimary endpoints, per the original sample size estimates. Age, baseline hormonal contraceptive use, race, and ethnicity were collected for preplanned subset analyses on the effect of these factors on efficacy endpoints (results reported elsewhere).

  • Doctors may prescribe sildenafil off-label for women based on individual assessment.
  • Patient education about realistic expectations is essential when using sildenafil.
  • Sildenafil’s mechanism involves enhancing nitric oxide signaling in blood vessels.
  • Women with liver or kidney problems need careful evaluation before sildenafil use.
  • Viagra was initially tested for women before focusing on men’s erectile issues.
  • Alternative options like vaginal lubricants are also common for female sexual problems.

The analysis was conducted with a mixed model for repeated measures, which handles missing data through maximum likelihood under the assumption of missing at random. For the nonprimary endpoints, we did not adjust for multiple hypothesis testing; therefore, all post hoc subset analyses are considered exploratory.

Why is this medicine prescribed?

All statistical analyses used SAS 9.4 or higher. The primary analysis of the SFQ28 (Arousal Sensation) and the FSDS-DAO (question 14) included a two-sided test with a significant level of 0.05. As shown in Figure 1, volunteers (n=833) and their sexual partners (n=605) underwent informed consent. Of the consented patients, 277 eligible participants entered the no-drug run-in period and 252 entered the single-blind placebo run-in period. A total of 200 participants were randomized to sildenafil cream (n=101) or placebo cream (n=99); 99 sildenafil cream–assigned women and 94 placebo cream–assigned women who received at least one dose of the investigational product made up the ITT population.

Flibanserin (Addyi)

A total of 174 women (sildenafil 90 and placebo 84) completed all study visits. Table 1 displays the baseline characteristics of participants and their sexual partners, if applicable, included in the safety analysis population. Demographic and Baseline Characteristics of Participants and Sexual Partners (Safety Population) Table 2 displays the efficacy results for the ITT population. Although the sildenafil cream group demonstrated greater improvement than the placebo cream group in the SFQ28 Arousal Sensation domain (P=.60), we did not find any statistically significant improvement in either coprimary efficacy endpoint during the double-blind dosing period (all P>.05) in the ITT population. There were no statistically significant differences in the mean number of satisfactory sexual events between sildenafil cream and placebo cream users at any point during the double-blind dosing period (all P>.32). The individual clinical interviews (conducted at enrollment) for the 174 participants in the intention-to-treat (ITT) population who completed all study visits were reviewed retrospectively. All participants had a main diagnosis of female sexual arousal disorder and sildenafil uk price were categorized according to the presence or absence of concomitant sexual dysfunction diagnoses or symptoms, including decreased desire, orgasmic dysfunction, and genital pain. The efficacy endpoints were then evaluated in an exploratory post hoc analysis by enrollment diagnoses groups and product assignment. All statistical analyses used SAS 9.4 or higher. The primary analysis of the SFQ28 (Arousal Sensation) and the FSDS-DAO (question 14) included a two-sided test with a significant level of 0.05. As shown in Figure 1, volunteers (n=833) and their sexual partners (n=605) underwent informed consent.

  • Clinical research into sildenafil for women includes various dosage trials.
  • Women using sildenafil should monitor blood pressure to avoid adverse effects.
  • The safety profile of sildenafil in women is less documented than in men.
  • Sildenafil’s impact on female sexual desire is still under scientific investigation.
  • Women should avoid sildenafil if pregnant or breastfeeding unless prescribed.
  • Alternative therapies for female sexual dysfunction include counseling and hormone therapy.

Of the consented patients, 277 eligible participants entered the no-drug run-in period and 252 entered the single-blind placebo run-in period. A total of 200 participants were randomized to sildenafil cream (n=101) or placebo cream (n=99); 99 sildenafil cream–assigned women and 94 placebo cream–assigned women who received at least one dose of the investigational product made up the ITT population. A total of 174 women (sildenafil 90 and placebo 84) completed all study visits. Table 1 displays the baseline characteristics of participants and their sexual partners, if applicable, included in the safety analysis population. Demographic and Baseline Characteristics of Participants and Sexual Partners (Safety Population) Table 2 displays the efficacy results for the ITT population. Although the sildenafil cream group demonstrated greater improvement than the placebo cream group in the SFQ28 Arousal Sensation domain (P=.60), we did not find any statistically significant improvement in either coprimary efficacy endpoint during the double-blind dosing period (all P>.05) in the ITT population. There were no statistically significant differences in the mean number of satisfactory sexual events between sildenafil cream and placebo cream users at any point during the double-blind dosing period (all P>.32). The mean proportion of satisfactory sexual events was also similar between the two dosing cohorts (all P>.15).

  • The market for female sexual enhancement drugs is growing, including sildenafil research.
  • Women should be aware of potential drug interactions when using sildenafil.
  • Female sexual health involves multiple factors, not just blood flow.
  • Sildenafil may not be effective for all women due to physiological differences.
  • Regular follow-up with healthcare providers can optimize treatment and safety.
  • Lifestyle factors such as stress and hormonal balance influence female libido.

The only statistically significant change noted for the ITT population was a statistically significant increase in the SFQ28 Desire domain score at week 8 for sildenafil cream users (P=.04, Table 2), which was a predefined exploratory endpoint. Efficacy Endpoints for the Intention-to-Treat Population* When the efficacy endpoints were compared in an exploratory post hoc analysis based on enrollment sexual dysfunction diagnoses, women with female sexual arousal disorder with concomitant orgasmic dysfunction did not experience as large a treatment benefit at week 12 from sildenafil cream use (data not shown, all P>.22) as those with other sexual dysfunction diagnoses. Specifically, women with female sexual arousal disorder as their only sexual dysfunction, although uncommon, experienced the largest improvements in sexual function at week 12 with sildenafil cream (Table 3), which were not statistically significant, likely because of the small sample size.

Why trust our experts?

When participants with female sexual arousal disorder with concomitant orgasmic dysfunction and female sexual arousal disorder with concomitant genital pain were removed from the analysis, a subset of participants (sildenafil 33 and placebo 32) remained.

Country Legal Status Prescription Required Notes
USA Approved for certain uses Yes Off-label for women often not approved
UK Prescription-only Yes Approved for male ED; off-label use in women
Canada Restricted use Yes Prescription required; variable by province
Australia Prescription-only Yes Limited clinical guidelines for women

This subset of participants, who had female sexual arousal disorder only or female sexual arousal disorder with concomitant decreased desire, experienced significant improvements with sildenafil cream use at week 12 in the coprimary endpoint of SFQ28 Arousal Sensation domain (P=.04, Table 3) and had large improvements in the SFQ28 Desire domain (P=.06, Table 3) and the SFQ28 Orgasm domain (P=.19, Table 3) at week 12 compared with placebo cream users.

We got busy with a full clinical study.

Assuming an estimated dropout rate of 25%, about 400–590 patients were planned to be randomized to the double-blind dosing period to ensure that a total of 300–440 patients successfully completed the double-blind dosing period (150–220 patients for each arm). Under the assumption of an SD of 4.7 for change from baseline to end of study in the SFQ28 Arousal Sensation domain and based on a previous study of oral sildenafil use in women with female sexual arousal disorder12 and a SD of 1.2 for change from baseline to end of study in question 14 of the FSDS-DAO, 300 patients would have provided more than 90% marginal power for the primary objective tests on the coprimary endpoints, with a target difference of +2 points in the change from baseline at week 12 in the SFQ28 Arousal Sensation domain and −0.5 in the change from baseline at week 12 in question 14 of the FSDS-DAO. Several studies further support the initial sample size calculations include.13–17 However, as a result of slower-than-anticipated enrollment (because of the requirement to obtain consent from and to enroll the patient's sexual partner and the effect of the coronavirus disease 2019 [COVID-19] pandemic) and considering the exploratory nature of the study, the sponsor decided that a smaller sample size, although resulting in underpowering, was acceptable and halted recruitment in August 2022. The protocol was revised to randomize 169–175 patients to ensure that a minimum of 150 patients completed the study, even though that sample size would not be sufficient to achieve the 300 patients estimated to provide more than 90% marginal power for the primary objective tests on the coprimary endpoints, per the original sample size estimates. Age, baseline hormonal contraceptive use, race, and ethnicity were collected for preplanned subset analyses on the effect of these factors on efficacy endpoints (results reported elsewhere).

Interactions with other medications

The analysis was conducted with a mixed model for repeated measures, which handles missing data through maximum likelihood under the assumption of missing at random. For the nonprimary endpoints, we did not adjust for multiple hypothesis testing; therefore, all post hoc subset analyses are considered exploratory. The individual clinical interviews (conducted at enrollment) for the 174 participants in the intention-to-treat (ITT) population who completed all study visits were reviewed retrospectively. All participants had a main diagnosis of female sexual arousal disorder and sildenafil uk price were categorized according to the presence or absence of concomitant sexual dysfunction diagnoses or symptoms, including decreased desire, orgasmic dysfunction, and genital pain. The efficacy endpoints were then evaluated in an exploratory post hoc analysis by enrollment diagnoses groups and product assignment. Efficacy Endpoints for Enrollment Female Sexual Dysfunction Diagnoses Subset Population* Although the subset population of women randomized to sildenafil cream with either female sexual arousal disorder only or female sexual arousal disorder with concomitant decreased desire did not demonstrate statistically significant decreased sexual distress as measured by the coprimary endpoint of FSDS-DAO question 14 (P=.95, Table 3), which assesses concern about difficulties with sexual arousal, we found that several other FSDS-DAO questions, which asked about generalized feelings related to sexual distress and interpersonal difficulties, showed significant improvement with sildenafil cream compared with placebo cream (questions 3, 5 and 10, all P≤.04, Table 3) in this exploratory subset.

  • Some women seek sildenafil for increasing genital blood flow and sensation.
  • The placebo effect can influence perceived benefits in women using sildenafil.
  • Women with cardiovascular risk should avoid sildenafil unless approved by a doctor.
  • Topical or alternative therapies might be considered alongside or instead of sildenafil.
  • Scientific consensus on sildenafil’s safety for women remains under development.
  • Proper dosing and medical oversight are key to minimizing risks.

The total FSDS-DAO score decreased by about 7 points for sildenafil cream users in the subset population (a clinically meaningful decrease in sexual distress11) compared with a 2-point decrease for placebo cream users (P=.10). Topical sildenafil cream used over 12 weeks among healthy premenopausal women with female sexual arousal disorder did not show statistically significant improvement over placebo in the coprimary (SFQ28 Arousal Sensation domain, FSDS-DAO question 14) or secondary (mean number and mean proportion of satisfactory sexual events) endpoints among the ITT population, all of whom had female sexual arousal disorder but had a wide variety of concomitant sexual dysfunction diagnoses or symptoms, during this exploratory phase 2b study.

This article is cited by

Participants applied the investigational product about 10–20 minutes before the sexual event. One gram was applied externally to the anterior labial commissure, prepuce of the clitoris, glans, frenulum, vestibule, and labia minora. The other gram was applied to the anterior distal vagina to an approximate depth of 0–3 cm or about halfway between the distal and proximal interphalangeal joints, targeting the distal, lower one-third of the vagina. Participants were instructed to wash off the cream and have their partner wash off the cream, if relevant, after the sexual experience. The Arousal Sensation domain of the SFQ28 questionnaire is made up of questions 6 through 9 (Appendix 2, available online at These four questions were answered using a Likert scale ranging from 1–5, with 1 being no sensation and 5 being a very strong sensation.

Let's do it.

The range of scores for the Arousal Sensation domain is 4–20, with higher scores indicating higher sexual function. The FSDS-DAO survey includes 15 questions, each of which began with the phrase, “How often in the past 30 days did you feel,” with responses of 0–4, with 0 indicating never feeling this way and 4 indicating always feeling this way (Appendix 2, Question 14 asks, “How often in the past 30 days did you feel concerned by difficulties with sexual arousal?” The range of scores for question 14 of the FSDS-DAO is 0–4, with lower scores indicating decreased levels of sexual distress. For the secondary efficacy endpoint, the electronic diary prompted women every 24 hours to report whether there had been a sexual event. If there was a sexual event, the electronic diary prompted the participant to answer several questions, including, “Did you consider sexual activity satisfactory for you?” The secondary endpoint was the change from baseline at week 12 in the average number and proportion of satisfactory sexual events per product cohort. Prespecified exploratory endpoints are detailed in Appendix 2, This study was designed as an exploratory, preliminary efficacy study. This study required the participants' main sexual dysfunction to be related to arousal because the mechanism of action of topical sildenafil citrate is to augment genital tissue blood flow to treat female sexual arousal disorder.18–28 Not surprisingly, we saw that female sexual arousal disorder was often accompanied by concomitant sexual dysfunction diagnoses or symptoms.29,30 When the efficacy endpoints were compared in an exploratory post hoc analysis among a subset of women with female sexual arousal disorder only or female sexual arousal disorder with concomitant decreased desire, we found either trends or significant improvements in sexual functioning with sildenafil cream compared with placebo cream across multiple aspects of sexual function.

What Would Viagra Do to a Woman?